The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To determine safety and tolerance of administering aerosolized recombinant interferon gamma (IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages by aerosolized IFN-gamma administration. To determine if subcutaneous (SC) injection of IFN-gamma can activate alveolar macrophages in AIDS patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Interferon-gamma; Interferons

Criteria

Inclusion Criteria

Patients must have:

• Diagnosis of AIDS with one or more opportunistic infections.

• Kaposi's sarcoma with prior history of opportunistic infection.

• Stable dose of zidovudine (AZT) therapy.

• Preserved pulmonary, renal and hepatic function.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

• Presence of active infection.

• Active opportunistic infections.

• Cardiac disease.

• Central nervous system disorders.

• History of seizures.

• Irreversible airway disease.

Patients with the following are excluded:

• Co-existing conditions and symptoms listed in Patient Exclusion Co-existing Conditions.

Prior Medication:

Excluded within 4 weeks of study entry:

• Immunosuppressive therapy.

• Cytotoxic therapy.

• Excluded:

• Interferon gamma therapy.